Scarica l'app Stockscreener
3.98
9.75%
-0.43
Pre-mercato:
3.95
-0.03
-0.75%
Quantum Biopharma Ltd Borsa (QNTM) Ultime notizie
Top Cannabis Stocks To Watch NowApril 4th - MarketBeat
QNTM Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Quantum BioPharma Ltd. (QNTM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Quantum BioPharma Ltd. (QNTM) stock price, news, quote and history - Yahoo Finance UK
QNTM Should I Buy - Intellectia AI
Quantum Biopharma Ltd. (QNTM) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied - Bitget
Cannabis Stocks To Watch TodayApril 2nd - MarketBeat
Quantum BioPharma Cleared to Proceed With $700 Million Market Manipulation Lawsuit After Motion to Dismiss Largely Denied - TipRanks
[6-K] Quantum Biopharma Ltd. Current Report (Foreign Issuer) | QNTM SEC FilingForm 6-K - stocktitan.net
Quantum BioPharma submits IND application for MS drug candidate By Investing.com - Investing.com South Africa
QNTM Stock Price, Quote & Chart | QUANTUM BIOPHARMA-B SUB VOT (NASDAQ:QNTM) - ChartMill
Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis - Sahm
Quantum BioPharma (QNTM) Files FDA Application for New MS Drug - GuruFocus
Promising Cannabis Stocks To Follow TodayApril 1st - MarketBeat
Quantum BioPharma up 5% as Submits IND Application For Lucid-MS - marketscreener.com
Quantum BioPharma Files FDA IND for Phase 2 Trial of Lucid-MS in Multiple Sclerosis - TipRanks
Quantum BioPharma submits investigational new drug (IND) application to United States Food and Drug Administration (FDA) - marketscreener.com
Quantum BioPharma submits IND application for MS drug candidate - Investing.com
Quantum BioPharma (QNTM) advances Lucid-MS with FDA IND for Phase 2 MS trial - Stock Titan
Top Cannabis Stocks To Keep An Eye OnMarch 31st - MarketBeat
Quantum BioPharma partners with Allucent for MS drug trial By Investing.com - Investing.com South Africa
Quantum BioPharma (QNTM) Plans Phase 2 Trial for Multiple Sclero - GuruFocus
Quantum BioPharma (QNTM) Partners with Allucent for Lucid-MS Pha - GuruFocus
Quantum BioPharma (QNTM) Plans Phase 2 Trial for Multiple Sclerosis Treatment - GuruFocus
Quantum BioPharma signs binding letter of intent with Allucent to conduct Phase 2 clinical trial in Multiple Sclerosis - marketscreener.com
Quantum BioPharma Taps Allucent for Phase 2 Trial of Novel MS Drug Lucid-MS - tipranks.com
Quantum BioPharma And Allucent Enter Binding Letter Of Intent For Phase 2 Clinical Trial In Multiple Sclerosis - marketscreener.com
Quantum BioPharma Partners with Allucent to Advance Phase 2 Clinical Trial of Lucid-MS for Multiple Sclerosis Treatment - Quiver Quantitative
Quantum BioPharma (QNTM) lines up Allucent for Lucid-MS Phase 2 trial - stocktitan.net
New MS treatment targeting demyelination moves toward Phase 2 - stocktitan.net
Portfolio Recap: Will Quantum BioPharma Ltd stock benefit from M A2026 Breakouts & Breakdowns & Safe Capital Growth Plans - baoquankhu1.vn
Quantum BioPharma Raises C$3.75 Million and Converts Debt in Capital Restructuring Push - TipRanks
Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis - Sahm
Quantum BioPharma Ltd.: Fundamental Analysis and Financial Ratings | 0K91 | CA74764Y2050 - marketscreener.com
Institution Moves: Will Quantum BioPharma Ltd outperform during market rallies - baoquankhu1.vn
Promising Cannabis Stocks To Add to Your WatchlistMarch 28th - MarketBeat
Can Quantum BioPharma Ltd generate free cash flow2026 Sector Review & Technical Pattern Based Buy Signals - baoquankhu1.vn
Quantum Biopharma Provides Corporate Update - Sahm
Quantum BioPharma reports $11.3M cash, runway to January 2028 By Investing.com - Investing.com South Africa
Quantum BioPharma Posts Strong 2025 Results, Extends Cash Runway and Advances MS and Alcohol Health Programs - TipRanks
Top Cannabis Stocks To Watch TodayMarch 27th - MarketBeat
Quantum Biopharma Maintains No Going Concern Status in Audited Financial Results for Fiscal Year 2025 - geneonline.com
Quantum BioPharma reports $11.3M cash, runway to January 2028 - Investing.com
Quantum BioPharma Ltd. Completes Phase 1 Trial for MS Drug Lucid-21-302 and Publishes unbuzzd™ Clinical Trial Results - Quiver Quantitative
Quantum Biopharma’s 2025 Audited Year End Financial Results Maintain ‘No Going Concern’ Status - marketscreener.com
Quantum BioPharma names principal investigator for MS trial By Investing.com - Investing.com Australia
Quantum BioPharma (FRA:0K91) NonCurrent Deferred Revenue : €0.00 Mil (As of Sep. 2025) - GuruFocus
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):